Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1992 Mar 1;175(3):655–659. doi: 10.1084/jem.175.3.655

Targeting autoantigen to B cells prevents the induction of a cell- mediated autoimmune disease in rats

PMCID: PMC2119141  PMID: 1740660

Abstract

Immunization protocols that induce high levels of delayed-type hypersensitivity are often associated with low levels of antibody production, whereas alternative immunization strategies can produce the opposite effect. This reciprocal relationship appears to depend, at least in part, on the fact that T cell-derived lymphokines that are predominantly involved in one type of response inhibit the development of those T cells that promote the alternative one. Such a regulatory mechanism is likely to be bistable in that whenever one form of response is established, spontaneous development of the alternative one will be inhibited. We have applied this concept to the control of a cell-mediated autoimmune disease in rats. By covalently linking the autoantigen to anti-IgD antibody, we have targeted it to B cells for presentation to antigen-specific T cells. This form of presentation favors antibody production and may be expected to antagonize the cell- mediated disease-inducing response to the same antigen. To test this hypothesis, use was made of the fact that experimental allergic encephalomyelitis (EAE), when induced with the encephalitogenic peptide of guinea pig myelin basic protein, is purely a cell-mediated disease. The experiments show that Lewis rats, immunized with the peptide in its encephalitogenic form, were protected from disease when simultaneously injected with the peptide coupled to anti-IgD monoclonal antibodies. Control experiments showed that neither peptide nor anti-IgD alone were protective, and the peptide covalently coupled to irrelevant antibodies also failed to protect. Spleen cells from animals protected from disease by the anti-IgD-peptide conjugate, when activated in vitro with the encephalitogen, were able to transfer EAE to naive recipients. The results demonstrate that a cell-mediated immune response can be controlled by appropriate targeting of the specific antigen without inducing T cell anergy and suggest a potential strategy for preventing autoimmune diseases that are essentially cell-mediated in type.

Full Text

The Full Text of this article is available as a PDF (504.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barclay A. N. The localization of populations of lymphocytes defined by monoclonal antibodies in rat lymphoid tissues. Immunology. 1981 Apr;42(4):593–600. [PMC free article] [PubMed] [Google Scholar]
  2. Brostoff S. W., Mason D. W. Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells. J Immunol. 1984 Oct;133(4):1938–1942. [PubMed] [Google Scholar]
  3. Daynes R. A., Araneo B. A. Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin 2 and interleukin 4. Eur J Immunol. 1989 Dec;19(12):2319–2325. doi: 10.1002/eji.1830191221. [DOI] [PubMed] [Google Scholar]
  4. Eynon E. E., Parker D. C. Do small B cells induce tolerance? Transplant Proc. 1991 Feb;23(1 Pt 1):729–730. [PubMed] [Google Scholar]
  5. Finkelman F. D., Snapper C. M., Mountz J. D., Katona I. M. Polyclonal activation of the murine immune system by a goat antibody to mouse IgD. IX. Induction of a polyclonal IgE response. J Immunol. 1987 May 1;138(9):2826–2830. [PubMed] [Google Scholar]
  6. Gajewski T. F., Schell S. R., Nau G., Fitch F. W. Regulation of T-cell activation: differences among T-cell subsets. Immunol Rev. 1989 Oct;111:79–110. doi: 10.1111/j.1600-065x.1989.tb00543.x. [DOI] [PubMed] [Google Scholar]
  7. Hashim G. A. Myelin basic protein: structure, function and antigenic determinants. Immunol Rev. 1978;39:60–107. doi: 10.1111/j.1600-065x.1978.tb00397.x. [DOI] [PubMed] [Google Scholar]
  8. Howell M. D., Winters S. T., Olee T., Powell H. C., Carlo D. J., Brostoff S. W. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science. 1989 Nov 3;246(4930):668–670. doi: 10.1126/science.2814489. [DOI] [PubMed] [Google Scholar]
  9. Hsiung L., Barclay A. N., Brandon M. R., Sim E., Porter R. R. Purification of human C3b inactivator by monoclonal-antibody affinity chromatography. Biochem J. 1982 Apr 1;203(1):293–298. doi: 10.1042/bj2030293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lanzavecchia A., Abrignani S., Scheidegger D., Obrist R., Dörken B., Moldenhauer G. Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets. J Exp Med. 1988 Feb 1;167(2):345–352. doi: 10.1084/jem.167.2.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Levine S., Sowinski R., Steinetz B. Effects of experimental allergic encephalomyelitis on thymus and adrenal: relation to remission and relapse. Proc Soc Exp Biol Med. 1980 Nov;165(2):218–224. doi: 10.3181/00379727-165-40961. [DOI] [PubMed] [Google Scholar]
  12. MacPhee I. A., Antoni F. A., Mason D. W. Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids. J Exp Med. 1989 Feb 1;169(2):431–445. doi: 10.1084/jem.169.2.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. MacPhee I. A., Day M. J., Mason D. W. The role of serum factors in the suppression of experimental allergic encephalomyelitis: evidence for immunoregulation by antibody to the encephalitogenic peptide. Immunology. 1990 Aug;70(4):527–534. [PMC free article] [PubMed] [Google Scholar]
  14. Mason D. Genetic variation in the stress response: susceptibility to experimental allergic encephalomyelitis and implications for human inflammatory disease. Immunol Today. 1991 Feb;12(2):57–60. doi: 10.1016/0167-5699(91)90158-P. [DOI] [PubMed] [Google Scholar]
  15. Mjaaland S., Fossum S. Modulation of immune responses with monoclonal antibodies. I. Effects on regional lymph node morphology and on anti-hapten responses to haptenized monoclonal antibodies. Eur J Immunol. 1990 Jul;20(7):1457–1461. doi: 10.1002/eji.1830200708. [DOI] [PubMed] [Google Scholar]
  16. Mosmann T. R., Coffman R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–173. doi: 10.1146/annurev.iy.07.040189.001045. [DOI] [PubMed] [Google Scholar]
  17. Owhashi M., Heber-Katz E. Protection from experimental allergic encephalomyelitis conferred by a monoclonal antibody directed against a shared idiotype on rat T cell receptors specific for myelin basic protein. J Exp Med. 1988 Dec 1;168(6):2153–2164. doi: 10.1084/jem.168.6.2153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Parish C. R., Liew F. Y. Immune response to chemically modified flagellin. 3. Enhanced cell-mediated immunity during high and low zone antibody tolerance to flagellin. J Exp Med. 1972 Feb 1;135(2):298–311. doi: 10.1084/jem.135.2.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Paterson P. Y. Experimental allergic encephalomyelitis and autoimmune disease. Adv Immunol. 1966;5:131–208. doi: 10.1016/s0065-2776(08)60273-4. [DOI] [PubMed] [Google Scholar]
  20. Pezzella F., Tse A. G., Cordell J. L., Pulford K. A., Gatter K. C., Mason D. Y. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol. 1990 Aug;137(2):225–232. [PMC free article] [PubMed] [Google Scholar]
  21. Roosnek E., Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med. 1991 Feb 1;173(2):487–489. doi: 10.1084/jem.173.2.487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sedgwick J. D., Mason D. W. The mechanism of inhibition of experimental allergic encephalomyelitis in the rat by monoclonal antibody against CD4. J Neuroimmunol. 1986 Dec;13(2):217–232. doi: 10.1016/0165-5728(86)90066-4. [DOI] [PubMed] [Google Scholar]
  23. Steinman L., Rosenbaum J. T., Sriram S., McDevitt H. O. In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc Natl Acad Sci U S A. 1981 Nov;78(11):7111–7114. doi: 10.1073/pnas.78.11.7111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Strejan G. H., Percy D. H., St Louis J., Surlan D., Paty D. W. Suppression of experimental allergic encephalomyelitis in guinea/pigs by liposome-associated human myelin basic protein. J Immunol. 1981 Nov;127(5):2064–2069. [PubMed] [Google Scholar]
  25. Swierkosz J. E., Swanborg R. H. Immunoregulation of experimental allergic encephalomyelitis: conditions for induction of suppressor cells and analysis of mechanism. J Immunol. 1977 Oct;119(4):1501–1506. [PubMed] [Google Scholar]
  26. Vandenbark A. A., Hashim G., Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature. 1989 Oct 12;341(6242):541–544. doi: 10.1038/341541a0. [DOI] [PubMed] [Google Scholar]
  27. Woollett G. R., Barclay A. N., Puklavec M., Williams A. F. Molecular and antigenic heterogeneity of the rat leukocyte-common antigen from thymocytes and T and B lymphocytes. Eur J Immunol. 1985 Feb;15(2):168–173. doi: 10.1002/eji.1830150211. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES